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Somatic mutations of DNMT3A occur in about 20% of acute myeloid leukemia (AML) patients. (ey mostly consist in het-
erozygous missense mutations targeting a hotspot site at R882 codon, which exhibit a dominant negative effect and are associated
with highmyeloblast count, advanced age, and poor prognosis. Other types of mutations such as truncations, insertions, or single-
nucleotide deletion also affect the DNMT3A gene, though with lower frequency. (e present study aimed to characterize two
DNMT3A gene mutations identified by next-generation sequencing (NGS), through analysis of protein stability and DNA
methylation status at CpG islands. (e first mutation was a single-nucleotide variant ofDNMT3A at exon 20 causing a premature
STOP codon (c.2385G>A; p.Trp795∗; NM_022552.4). (e DNMT3A mutation load increased from 4.5% to 38.2% during
guadecitabine treatment, with a dominant negative effect on CpG methylation and on protein expression. (e second mutation
was a novel insertion of 35 nucleotides in exon 22 ofDNMT3A (NM_022552.4) that introduced a STOP codon too, after the amino
acid Glu863 caused by a frameshift insertion (c.2586_2587insTCATGAATGAGAAAGAGGACATCTTATGGTGCACT; p.
(r862_Glu863fsins). (e mutation, which was associated with reduced DNMT3A expression and CpG methylation, persisted at
relapse with minor changes in the methylation profile and at protein level. Our data highlight the need to better understand the
consequences of DNMT3A mutations other than R882 substitutions in the leukemogenic process in order to tailor patient
treatments, thus avoiding therapeutic resistance and disease relapse.
1. Introduction
Genetic alterations of chromatin regulators and epigenetic
modifications cooperate to the pathogenesis of acute mye-
loid leukemia (AML) [1]. Among epigenetic modifications,
DNA methylation represents a mechanism adopted by cells
to regulate DNA accessibility through the conversion of 5-
methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-
hmC). It switches on/off the promoter of several target
genes, thus regulating their expression levels and contrib-
uting to disease phenotype. DNA methyltransferases
(DNMT3A, DNMT3B, DNMT1, and DNMT3L) are the key
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enzymes involved in DNA methylation. DNMT3A and
DNMT3B produce de novo hemimethylated DNA and de
novo symmetric DNA methylation, respectively, while
DNMT1 is involved in maintenance of DNA methylated
status [2, 3].
DNA methylation has been identified as a specific
functional category of mutated genes in AML that includes
mutation in DNMT3A, DNMT3B, DNMT1, Tet methyl-
cytosine dioxygenase 1 and 2 (TET1, TET2), and isocitrate
dehydrogenase 1 and 2 (IDH1, IDH2) genes [4]. Moreover,
Wilms tumor 1 (WT1) mutations were shown to reduce
DNA methylation levels significantly in AML patients,
conferring the same hypomethylation signature observed in
patients harbouring TET2mutations [5]. Haploinsufficiency
of WT1 in preclinical models was also shown to decrease 5-
hmC levels and impair TET2 function, especially in elderly
animals [6].
DNMT3Amutations are among the most frequent driver
mutations in AML, third for frequencies to Fms-like tyrosine
kinase 3 (FLT3) and nucleophosmin 1 (NPM1) [1]. About
20% of patients with de novo AML show recurrent somatic
mutations in the DNMT3A gene [7], which represents an
early lesion in leukemia development. Indeed, DNMT3A
genomic alterations are considered a preleukemic event in
hematopoietic stem cells (HSCs) and confer a proliferation
advantage [8]. (ey have been identified in preleukemic
stem cells of myelodysplastic syndrome (MDS) and AML
patients [9]. Moreover, mutations in genes encoding epi-
genetic modifiers, including TET2, ASXL transcriptional
regulator 1 (ASXL1), and DNMT3A have been reported in
aging healthy people and are considered the first “hit” for the
“clonal hematopoiesis of indeterminate potential (CHIP)”
[10, 11].
Genomic lesions of the DNMT3A gene mostly consist in
missense mutations targeting a hotspot site at R882 codon,
which exhibits a dominant negative effect [12]. Furthermore,
DNMT3A R882 mutations are associated with a hypo-
methylated status of CpG islands, higher relapse rate, and
poor prognosis [13–18], and they persist during remission
[19, 20]. It has been recently shown that the methylation
levels are dependent on the amount of active DNMT3A and
higher methylation confers a better prognosis to AML pa-
tients [21]. Among patients carrying DNMT3A mutations,
15–20% do not show the substitution at R882 codon, but
they harbour truncations, insertion, or single-copy deletions
[1, 7].
(e present study aimed to characterize two undescribed
DNMT3A mutations identified by next-generation se-
quencing (NGS) in two different AML patients, through
analysis of protein stability and DNA methylation status at
CpG islands.
2. Materials and Methods
2.1. Patients. Samples were obtained from AML patients
after informed consent was approved by the Institutional
Ethical Committee (protocol 112/2014/U/Tess of Policlinico
Sant’Orsola-Malpighi) in accordance with the Declaration of
Helsinki.
2.2. Isolation of Mononuclear Cells. Bone marrow (BM)
mononuclear cells were isolated by Ficoll density-gradient
(Amersham Biosciences) and lysed in guanidine-thiocya-
nate-containing lysis buffer (RLT, Qiagen, Ltd).
2.3. Genomic DNA, RNA, and Protein Extraction. (e All-
Prep DNA/RNA/Protein Mini Kit (Qiagen, Ltd) was used to
extract DNA, RNA, and protein from primary mononuclear
cells according to the manufacturer’s instructions.
2.4. Ion Torrent Next-Generation Sequencing and Variant
Calling. (e patients’ mutational profile was determined
using Oncomine Myeloid Research Assay. (e libraries
were quantified using the Ion Library TaqMan TM
Quantitation Kit ( ermo Fisher Scientific) following
manufacturer’s instructions and run in the Ion 530™ chip
on the Ion Torrent S5 instrument ( ermo Fisher Scien-
tific). Sequence alignment and analysis were performed
using the Ion Torrent Suite Software v.5.8.0 and the Ion
Reporter software v.5.10.3.0 and v.5.10.5.0 ( ermo Fisher
Scientific). Human genome build 19 (Hg 19) was used as
the reference for sequence alignment. A minimum cov-
erage depth per amplicon of 500 was required; non-
synonymous mutations with a variant allele frequency
(VAF) ≥2.5% were reported; 5′ and 3′ untranslated regions
(UTRs), intronic donor splice-site variants, and poly-
morphisms were filtered out.
2.5. Amplification and Sanger Sequencing. DNMT3A mu-
tations were confirmed by Sanger sequencing. Briefly, re-
verse transcription was performed starting from 1 μg of RNA
using reverse transcriptase M-MuLV enzyme (Sigma-
Aldrich®). (e obtained cDNA was used to perform poly-merase chain reaction (PCR) using Applied Biosystem
AmpliTaq Gold® ( ermo Fisher Scientific) and the fol-lowing primers: FW: 5′-TCGAGTCCAACCCTGTGATG-3′
and REV: 5′-TAACTTTGTGTCGCTACCT CAGTT-3′.
Cycling conditions were as follows: 10 minutes at 95°C; 40
cycles: 30 seconds at 94°C; 45 seconds at 54°C; 30 seconds at
72°C; and 10 minutes at 72°C. PCR amplicons were purified
using Applied Biosystems ExoSAP-IT™ PCR Product
Cleanup Reagent ( ermo Fisher Scientific) according to
manufacturer’s instructions. Samples were sequenced
according to dideoxy procedure BigDye® Terminator v3.1Cycle Sequencing Kit ( ermo Fisher Scientific) on an
Applied Biosystems 3730xL genetic analyzer system
( ermo Fisher Scientific).
2.6. Capillary Electrophoresis. (e allelic ratio of FLT3-ITD
was measured by capillary electrophoresis. (e reaction was
performed starting from 20 μg of DNA, by using AmpliTaq™
Gold DNA polymerase enzyme, Buffer II, magnesium
chloride ( ermo Fisher Scientific) and the following
primers: forward, 5′-GCAATTTADGTATGAAAGC-
CAGC-3′, and reverse, 5′-CTTTCAGCATTTTGACGGCA-
ACC-3′. Cycling conditions were 10 minutes at 95°C; 30
seconds at 95°C; 60 seconds at 60°C; 60 seconds at 72°C for 35
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cycles; 7 minutes at 72°C. (e amplification products were
sequenced on Applied Biosystems 3130 Genetic Analyzer
( ermo Fisher Scientific) and were analyzed with Gen-
eMapper™ Software 5 ( ermo Fisher Scientific). (e ratio
of the area of mutated and wildtype (wt)-FLT3 defined the
allelic ratio.
2.7. Western Blot Analysis. Protein extracts were separated
by sodium dodecyl sulphate-polyacrylamide gel electro-
phoresis (SDS-PAGE, Bio-Rad) and transferred onto ni-
trocellulose membranes. (e following antibodies were
used: rabbit anti-DNMT3A (D23G1; Cell Signaling Tech-
nologies) and goat anti-β-actin (Santa Cruz Biotechnology)
as control; horseradish peroxidase (HRP)-conjugated anti-
rabbit immunoglobulin (Ig)G (GEHealthcare) and anti-goat
IgG (Santa Cruz) as secondary antibodies. ECL Prime (GE
Healthcare) reagent was used for detection using ChemiDoc
XRS+ System (Bio-Rad). Signal quantification was per-
formed using Image J software.
2.8. DNAMethylationAssay. Methylation was quantified on
total DNA using the MethylFlash Methylated DNA 5-mC
Quantification Kit (Epigentek) using triplicates of 100 ng of
DNA from each sample. (e absorbance (OD) was read at
450 nm using the Multiskan EX automatic microplate reader
( ermo Fisher Scientific). To quantify the absolute amount
of methylated DNA, we generated a standard curve using a
negative control (ME3) and 5 dilutions of positive control
(10.0; 5.0; 2.0; 1.0; 0.5 ng/μl); next we determined the slope
(OD/ng) using linear regression. According to manufac-
turer’s instructions, we used the following formulas to
calculate the amount and percentage of 5-mC:
5mC(ng) �
(sampleOD − ME3OD)
slope × 2∗ ,
5mC(%) �
5mC(ng)
sampleDNA(ng) × 100
,
(1)
Where ∗2 is a factor to normalize the positive control be-
cause it contains only 50% of 5mC.
3. Results and Discussion
3.1. Identification of a Premature Stop Codon in Exon 20
of the DNMT3A Gene in AML. NGS on a primary AML
sample identified a single-nucleotide variant ofDNMT3A at
exon 20 causing a premature STOP codon (c.2385G >A;
p.Trp795Ter) that was confirmed by Sanger sequenc-
ing (Figure 1(a)). Mutations at codon 795 were previ-
ously reported in angioimmunoblastic T-cell lymphoma
(p.Trp795_Gly796ins3) [22] and in refractory anemia
evolving to secondary AML (Trp795Cys) [23]. A STOP
codon at position 795 has been reported in the Leiden Open
Variation Database (c.2384G >A, https://www.lovd.nl/)
and the c.2385G>Amutation has been found annotated in
the database of single-nucleotide polymorphisms (dbSNP,
rs1395575712). Moreover, missense variants affecting the
codon 795 (chr2:25462024:A >C and chr2:25462024:
A >G) were also annotated in the Genome Aggregation
Database (gnomAD) with an allelic frequency of
0.000003979 and 0.000007957, respectively (https://
gnomad.broadinstitute.org/). We detected the mutation
(VAF � 4.5%) in the BM sample of a 74-year-old woman
(AML#1), with 70% of AML blasts at diagnosis, normal
karyotype, wt-FLT3, NPM1, and tumor protein p53 (TP53)
and intermediate cytogenetic risk according to ELN 2017
[24]. Mutations of IDH2 (c.515G >A; p.Arg172Lys), BCL6
corepressor (BCOR) (c.2915_2916insA; p.Tyr972Ter), and
TET2 (c.3641G >A; p.Arg1214Gln) were also detected in
the patient, with a VAF of 6.1%, 4.8%, and 3.2%, re-
spectively (Figure 1(b) and Table 1). Previous evidence
reported the co-occurrence of DNMT3A lesions with
mutations of NPM1, IDH2, and TP53 and with those af-
fecting genes involved in chromatin and splicing in AML
cases [25]. (e patient received an induction therapy with
the DNMTinhibitor guadecitabine [26], with persistence of
disease at the bone marrow evaluation after 4 courses of
therapy (40% of blasts and stable cytogenetic risk). (e
DNMT3A mutation load increased to 38.2% in the sample
evaluated 4 months after treatment. NGS analysis revealed
an increasing VAF during treatment of the IDH2 (6.1% to
39.8%) and BCOR mutations (4.8% to 42.1%) detected at
diagnosis, along with the emergence of a TP53 mutation
(c.607G >A; p.Val203Met, VAF 5.3%, Figure 1(b) and
Table 1), which was not detectable at diagnosis. Nowadays,
no predictive marker of response to guadecitabine has been
defined for newly diagnosed AML. However, Chung et al.
reported no significant association between gene mutations
and complete remission in a cohort of 128 relapsed/re-
fractory AML [27]. Trends were observed for TET2-mu-
tated cases (higher CR rate) and IDH1/2-mutated and
TP53-mutated AML (resistance). Moreover, TET2 muta-
tions have been associated with increased response to
hypomethylating agents in MDS [28, 29] and AML with
low blast count [28]. We believe that our results suggest the
persistence during treatment of a minor clone harbouring
DNMT3A, IDH2, and BCOR mutations, which was posi-
tively selected and progressively expanded, along with the
acquisition of a novel TP53-mutated subclone. In parallel,
TET2-mutated blasts were killed by the treatment.
3.2. Detection of aNovel 35Nucleotides Insertion in Exon 22 of
theDNMT3AGene inAML. Targeted deep sequencing leads
to the identification of an additional DNMT3A genetic al-
teration consisting in a new insertion of 35 nucleotides in
exon 22 of the DNMT3A gene causing the amino acid
change Glu863Ser followed by a premature STOP codon
(c.2586_2587ins35:TC ATGAATGAGAAAGAGGACATC-
TTATGGTGCAC; p. (r862_Glu863fsins, Figure 2(a)). (e
variant, which has never been reported before, was detected
in primary leukemic cells isolated from a 63-year-old woman
(AML#2), with 80% of blasts in the BM at diagnosis and
90% at relapse.(e patient had normal karyotype, low FLT3-
ITD allelic burden (c.1747_1748ins57: GCTCCTCAGA-
TAATGAGTACTTCTACGTTGATTTCAGAGAATATG-
AATATGATCCAA; VAF: 11.7% at diagnosis), and
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Figure 1: Sanger sequencing of the DNMT3A single-nucleotide variant identified in AML#1 and analysis of clonal evolution based on NGS
data. (a) AML#1 showed a single-nucleotide variant of DNMT3A at exon 20 causing a premature STOP codon (c.2385G>A; p.Trp795∗;
NM_022552.4). (b) Variant allele frequency (VAF) changes of the detected mutations at diagnosis and follow-up (after 4 courses of
guadecitabine therapy), showing expansion of the DNMT3A-mutated clone.
Table 1: Mutational profile of AML#1 at diagnosis and follow-up.
Pt Gene Locus NM_ID Exon Type Coding Amino acidchange VAF (%)
Variant
effect
AML#1Dx
DNMT3A chr2:25462022 NM_022552.4 20 SNV c.2385G>A p.Trp795Ter 4.45 Nonsense
TET2 chr4:106164773 NM_001127208.2 6 SNV c.3641G>A p.Arg1214Gln 3.20 Missense
IDH2 chr15:90631837 NM_002168.3 4 SNV c.515G>A p.Arg172Lys 6.06 Missense
BCOR ChrX:39931683 NM_001123385.1 4 INDEL c.2915_2916insA p.Tyr972Ter 4.76 Nonsense
AML#1F-UP
DNMT3A chr2:25462022 NM_022552.4 20 SNV c.2385G>A p.Trp795Ter 38.20 Nonsense
IDH2 chr15:90631837 NM_002168.3 4 SNV c.515G>A p.Arg172Lys 39.80 Missense
TP53 chr17:7578242 NM_000546.5 6 SNV c.607G>A p.Val203Met 5.25 Missense
BCOR chrX:39931683 NM_001123385.1 4 INDEL c.2915_2916insA p.Tyr972Ter 42.08 Nonsense
Pt: patient; Dx: diagnosis; F-UP: follow-up; SNV: single-nucleotide variant; INDEL: insertion/deletion; ins: insertion.
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Figure 2: Continued.
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intermediate cytogenetic risk according to the ELN 2017
classification [24]. Molecular analysis also detected mu-
tations of NPM1 (c.863_864insCTTG; p.Trp288fs; VAF
37.4%) and TET2 (c.395delA; p.Asn132fs; VAF 38.6% and
c.5504delG; p.Gly1835fs; VAF 43.6%, Figure 2(b) and
Table 2). (e patient started fludarabine, arabinosyl cy-
tosine, and idarubicin (FLAI-5) induction regimen [30, 31]
and obtained complete hematological remission onemonth
later, with undetectable FLT3mutations. After 7 months of
complete remission, the patient relapsed. Mutational
analysis performed on the diagnosis and relapse samples
showed that the DNMT3A mutation loads were, re-
spectively, 35.8% and 42.5%. (e relapse sample presented
an increase of 5.5% for VAF of NPM1mutation, along with
an expanded FLT3-ITD clone (11.7% to 40.1%), the per-
sistence of TET2 mutations with a slight VAF increase
(c.395delA; p.Asn132fs; VAF 48.4% and c.5504delG;
p.Gly1835fs; VAF 49.7%), acquisition of a WT1 mutation
(c.1109G>C; p.Arg370Pro; VAF: 48.3%; Figure 2(b) and
Table 2). In this patient, the treatment was not able to
eradicate the leukemic clone harbouring TET2, DNMT3A,
and NPM1 mutations, which seems to have acquired an
additional WT1 mutation at relapse. Moreover, AML re-
lapse was characterized by the expansion of the FLT3-ITD
clone that was reduced but not eradicated by the treatment,
with an increase of allelic ratio from 0.09 (diagnosis) to 0.21
(relapse). A recent study showed that the persistence of
DNMT3A mutation at a VAF ≥2% at first remission is a
common event in AML, occurring in 65% of cases with
mutation at diagnosis and is associated with older age and
inferior relapse-free survival [32].
3.3. Ce Identified DNMT3A Mutations Alter DNA CpG Is-
lands Methylation and Protein Stability. To investigate the
functional consequences of the identified mutations, we
performed methylation analysis of CpG islands on DNA
extracted from primary leukemic samples of both patients.
Our cases showed DNA hypomethylation in comparison
with primary AML samples with wt-DNMT3A gene or
R882H mutation (VAF 37.0%) (Figure 3(a)). In the sample
carrying Trp795∗ mutation, CpG islands methylation shifted
from 47.1% at diagnosis to 24.4% at follow-up (p � 0.020), in
accordance with the increase in the mutations allelic burden
(from 4.5% at diagnosis to 38.2% at follow-up). At follow-up,
CpG methylathion was significantly reduced compared with
the wt-DNMT3A sample (p � 0.017). However, the ob-
served hypomethylation status may be associated both with
hypomethylating agent treatment and with the expansion of
the DNMT3A-mutated clone during treatment.
In the sample carrying the insertion at (r862_Glu863,
CpG island methylation at diagnosis was significantly re-
duced compared with the wt-DNMT3A sample (p � 0.047).
Moreover, its levels were similar to those observed in the
R882H sample. No major changes occurred between disease
diagnosis and relapse in terms of CpG methylation level and
DNMT3A (c.2586_2587ins35; p. (r862_Glu863fsins) VAF.
(e results suggest that the identified mutations induce
DNMT3A loss of function, similarly to the R882H alteration.
It has been recently shown that hypomethylation is an
initiating feature of AML with DNMT3AR882 [33] and that
demethylator phenotypes, which are partially related to
DNMT3A mutational status, have a prognostic role, in-
dependent of age and cytogenetic abnormalities [34]. Future
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Figure 2: Sanger sequencing of the insertion in theDNMT3A gene identified in AML#2 and analysis of clonal evolution based on NGS data.
(a) AML#2 showed a novel insertion of 35 nucleotides in the exon 22 of the DNMT3A gene (c.2586_2587ins35: TCATGAATGAG
AAAGAGGACATCTTATGGTGCAC; p(r862_Glu863fsins). (b) Representation of clonal evolution of AML#2 from diagnosis to relapse
(that occurred after 7 months of complete remission achieved with FLAI-5 chemotherapy regimen).
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analyses of the aberrant DNA methylation pattern may help
define specificities compared with DNMT3AR882 AML and
novel potential silenced or activated enhancers involved in
leukemogenesis [35].
To understand whether alterations in DNMT3A protein
expression were responsible for the observed changes in
CpG methylation, we performed western blot on BM
samples at different time points. Protein analysis revealed
that despite the low DNMT3A mutation burden in the
diagnosis sample of the case AML#1 (Trp795∗), DNMT3A
protein levels were reduced to 72% and 21% compared
with wt-DNMT3A and R882H samples, respectively
(Figure 3(b)). Furthermore, the increased VAF of truncated
DNMT3A was associated with no detectable protein in the
follow-up sample (Figure 3(b)). Despite the heterozygous
mutational status, the wt protein isoform became un-
detectable. We speculated that the wt protein was unable to
form a heterodimer with the truncated DNMT3A form,
Table 2: Mutational profile of AML#2 at diagnosis and relapse.
Pt Gene Locus NM_ID Exon Type Coding Amino acidchange
VAF
(%)
Variant
effect
AML#2Dx
DNMT3A chr2:25458586 NM_022552.4 22 INDEL c.2586_2587ins
∗ p.Glu863Ser 35.79 Nonsense
TET2 chr4:106155491 NM_001127208.2 3 INDEL c.395delA p.Asn132fs 38.55 fs del
TET2 chr4:106197168 NM_001127208.2 11 INDEL c.5504delG p.Gly1835fs 43.60 fs del
NPM1 chr5:170837545 NM_002520.6 11 INDEL c.863_864insCTTG p.Trp288fs 37.41 fs ins
FLT3 chr13:28608308 NM_004119.2 14 INDEL c.1747_1748ins
∗∗ p.Gly583_Ser584ins∗∗∗ 11.70 Nonfs ins
AML#2R
DNMT3A chr2:25458586 NM_022552.4 22 INDEL c.2586_2587ins
∗ p.Glu863Ser 42.45 Nonsense
TET2 chr4:106155491 NM_001127208.2 3 INDEL c.395delA p.Asn132fs 48.34 fs del
TET2 chr4:106197168 NM_001127208.2 11 INDEL c.5504delG p.Gly1835fs 49.65 fs del
NPM1 chr5:170837545 NM_002520.6 11 INDEL c.863_864insCTTG p.Trp288fs 42.87 fs ins
WT1 chr11:32417943 NM_024426.4 7 SNV c.1109G>C p.Arg370Pro 48.25 Missense
FLT3 chr13:28608308 NM_004119.2 14 INDEL c.1747_1748ins
∗∗ p.Gly583_Ser584ins∗∗∗ 40.10 Nonfs ins
Pt: patient; Dx: diagnosis; R: relapse; SNV: single-nucleotide variant; INDEL: insertion/deletion; ins: insertion; fs: frameshift; del: deletion; ∗insertion of 35
nucleotides: TCATGAATGAGAAAGAGGACATCTTATGGTGCAC; ∗∗insertion of 57 nucelotides: GCTCCTCAGATAATGAGTACTTCTACGTTGA-
TTTCAGAGAATATGAATATGATCCA; ∗∗∗SerSerAspAsnGluTyrPheTyrValAspPheArgGluTyrGluTyrAspProSer.
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Figure 3: Effect of DNMT3A mutations on protein function and expression. (a) CpG islands methylation analysis. (e bars represent
mean± standard deviation (SD) of the absolute 5-mC level (percentage of 5-mC left axis; SD values are barely detectable due to low values).
Dots represent theDNMT3AVAF in the analyzed samples (right axis). A BM sample from anAML patient harbouring theDNMT3AR882H
mutation (VAF 37.0%) was used for comparison (wt: wildtype; R882H: canonical mutation; Dx: diagnosis; F-UP: follow-up; R: relapse). (b)
Western blot analyses of DNMT3A expression in representative AML cases with wt-DNMT3A and R882H mutation, followed by diagnosis
and follow-up of AML#1, diagnosis and relapse of AML#2 (wt: wildtype; Dx: diagnosis; F-UP: follow-up; R: relapse). β-actin was used for
loading normalization and quantification. Numbers represent DNMT3A levels normalized on the wt sample.
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which may also be unstable, thus causing a premature
degradation. (is hypothesis is supported by a recent study,
which demonstrates that DNMT3A truncation mutations
have a dominant negative effect with loss of function and
haploinsufficiency in AML [12]. On the contrary, DNMT3A
protein was detectable in the analyzed samples from AML#2
(p.(r862_Glu863fsins). In this patient, we observed that
DNMT3A levels were reduced in the diagnosis sample
compared with the wt one and were similar to those obtained
in the R882H-mutated case (Figure 3(b)). DNMT3A ex-
pression slightly increased in the relapse sample, showing a
30% reduction in protein level compared with the wt sample.
(e data suggest that the mutation, which is predicted to
introduce a premature STOP codon, interferes with protein
expression but does not alter the stability of the wt protein.
Future investigation will be useful to demonstrate if the
presence of a portion of the catalytic domain in this trun-
cated protein allows it to bind to wt-DNMT3A. Taken to-
gether, the protein and methylation analyses indicate that
this mutation results in decreased DNMT3A expression and
function.
4. Conclusions
DNMT3A mutations are becoming highly relevant in he-
matological malignancies, thanks to NGS technologies
which allow us to better characterize myeloid disorders. In
this study, we presented two mutations of the DNMT3A
gene never described in AML and investigated their con-
sequences on protein expression and function. Both mu-
tations localized in the catalytic domain of the DNMT3A
protein and were predicted to cause loss of function.(e first
one is responsible for a truncated, nondetectable protein
associated with hypomethylation of CpG islands, which
expanded under the pressure of hypomethylating agent
treatment. (e second mutation was an insertion of 35
nucleotides, with a hypomethylation pattern, suggesting a
negative effect on CpG methylation mediated by mutant
DNMT3A. (e DNMT3A-mutated clone escaped therapy
selection and likely acquired aWT1mutation. Both patients
showed evidence of clonal evolution, resulting from the
selective pressure induced by treatment. Our strategy, based
on bulk sequencing, allows us to draw a picture of AML-
related mutations, along with their frequency and to spec-
ulate on mutation co-occurrence at disease diagnosis and
progression. However, a single-cell sequencing approach is
needed to precisely evaluate the clonal complexity of AML
across the different disease stages, drive conclusions on the
clonal and subclonal architecture, and uncover genomic
trajectories of leukemia evolution [36–39]. (e presence of
cooperating mutations and their contribution to the leu-
kemic phenotype along with the identified DNMT3A mu-
tations deserve further investigation. Our data highlight the
need to characterize and monitor patient-specific genomic
alterations in AML, in order to tailor treatments and allow
early detection of expanding subclonal population. More-
over, future studies are needed to define the hypo-
methylation pattern resulting from the described genomic
lesions and its cooperation with differentiation stage-specific
histone modification in the regulation of the leukemogenic
transcriptional program.
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